# Batch Risk of Bias Eval Report

This report contains an audit trace: explicit extracted evidence, model-provided rationales, and label comparisons. It does not include hidden chain-of-thought.

- Studies: 4
- Domains: 20
- Accuracy: 11/20 (55.0%)

## Summary

| PMID | Study | Correct | Accuracy | Seconds |
|---|---|---:|---:|---:|
| 19487623 | King 2009 | 3/5 | 60.0% | 62.46 |
| 20579848 | Palacios 2009 | 2/5 | 40.0% | 95.67 |
| 21775755 | Ziegler 2011 | 3/5 | 60.0% | 89.05 |
| 23148458 | Sheridan 2012 | 3/5 | 60.0% | 92.43 |

## Error Types

- under-called_due_to_missing_or_underused_evidence: 5
- blinding_outcome_type_or_role_confusion: 2
- over-inferred_from_sparse_reporting: 2

## 19487623 - King 2009

- Mode: strict
- Review context: none (0 chars)
- Article chars: 24566
- Extraction context chars: 12006
- Total seconds: 62.46

### Methodology Extraction

- `randomization_method`: Participants were randomly assigned to citalopram or placebo using permuted blocks with randomly varying block sizes stratified by site and by age (5-11 vs 12-17 years).
- `allocation_concealment_method`: Not reported
- `blinding_participants`: Placebo matched for smell, taste, and viscosity was prepared at each site's pharmacy according to study specifications.
- `blinding_personnel`: Two masked clinicians met with participants during each scheduled evaluation. The evaluating clinician monitored efficacy and was blinded to adverse events. The treating clinician reviewed efficacy ratings, monitored and recorded adverse events, and subsequently adjusted the medication dosage as clinically indicated.
- `blinding_outcome_assessors`: The evaluating clinician monitored efficacy and was blinded to adverse events. Evaluating clinicians from all sites were trained to reliability on the CYBOCS-PDD, CGI-I, and Clinical Global Impressions, Severity of Illness Scale at the beginning and midpoint of the trial.
- `attrition_details`: 149 were randomized to receive citalopram (n=73) or placebo (n=76). Most participants (82.6%) completed the 12-week trial. In the citalopram-treated group, 12.3% stopped early due to adverse events and another 2.7% withdrew consent; in the placebo group, 9.2% left early owing to adverse events and another 6.6% withdrew consent. For subjects who failed to complete all postrandomization assessments, the last observation was carried forward.
- `study_design`: Randomized controlled trial (parallel-group individual RCT).
- `additional_notes`: Liquid citalopram (Celexa, 10 mg/5 mL) was obtained commercially. Placebo matched for smell, taste, and viscosity was prepared at each site's pharmacy according to study specifications. The trial, NCT00086645, was registered at clinicaltrials.gov before initiation and was conducted at 6 academic medical centers. All efficacy and safety analyses used the intent-to-treat principle.

### Domain Judgements

| Domain | Pred | GT | Match | Error Type |
|---|---|---|---|---|
| Random sequence generation | Low risk | Unclear risk | no | over-inferred_from_sparse_reporting |
| Allocation concealment | Unclear risk | Unclear risk | yes |  |
| Blinding of participants and personnel: All outcomes | Low risk | Low risk | yes |  |
| Blinding of outcome assessment: All outcomes | Low risk | Low risk | yes |  |
| Incomplete outcome data: All outcomes | Low risk | Unclear risk | no | over-inferred_from_sparse_reporting |

### Audit Details

#### Random sequence generation

- Prediction: Low risk
- Ground truth: Unclear risk
- Match: False
- Model rationale: The study explicitly reports a random component (permuted blocks with randomly varying block sizes stratified by site and age), which satisfies the RoB 1.0 criteria for adequate random sequence generation and indicates low risk of selection bias from sequence generation.
- Model support: Quote: "Participants were randomly assigned to citalopram or placebo using permuted blocks with randomly varying block sizes stratified by site and by age (5-11 vs 12-17 years)." Comment: Probably done — a clear random component (permuted blocks with randomly varying block sizes) is described, which meets the criteria for low risk of bias for sequence generation.
- Model support context: [{"source": "methodology", "quote": "Participants were randomly assigned to citalopram or placebo using permuted blocks with randomly varying block sizes stratified by site and by age (5-11 vs 12-17 years).", "relevance": "Direct description of the random sequence generation method showing use of a random component (permuted blocks with random block sizes), which supports low risk."}, {"source": "methodology", "quote": "Randomized controlled trial (parallel-group individual RCT).", "relevance": "Confirms trial design context in which appropriate randomization was implemented."}]
- GT support: Participants were randomly assigned to citalopram or placebo using permuted blocks with randomly varying block sizes stratified by site and by age (5-11 vs 12-17 years)
- Evidence row: {}
- Source context preview: 

#### Allocation concealment

- Prediction: Unclear risk
- Ground truth: Unclear risk
- Match: True
- Model rationale: Random sequence generation is reported, but there is no information about procedures that would prevent recruiters/enrollers from foreseeing assignments (central randomization, sealed envelopes, or pharmacy-controlled allocation). Because concealment is not described, risk of selection bias cannot be determined.
- Model support: Comment: Allocation concealment method not reported in the manuscript; randomization method (permuted blocks with varying block sizes, stratified by site and age) is described but there is no information that assignments were concealed (central allocation, sealed envelopes, or pharmacy-controlled randomization) prior to enrolment.
- Model support context: [{"source": "methodology", "quote": "Participants were randomly assigned to citalopram or placebo using permuted blocks with randomly varying block sizes stratified by site and by age (5-11 vs 12-17 years).", "relevance": "Shows an adequate random sequence generation method but does not provide information on whether allocations were concealed."}, {"source": "methodology", "quote": "allocation_concealment_method: Not reported", "relevance": "Explicitly indicates the manuscript did not report how allocation was concealed, which is critical to judge selection bias risk."}, {"source": "methodology", "quote": "Placebo matched for smell, taste, and viscosity was prepared at each site's pharmacy according to study specifications.", "relevance": "Indicates placebo was prepared locally, but does not confirm whether the pharmacy or another central mechanism controlled allocation concealment...
- GT support: Details not provided
- Evidence row: {}
- Source context preview: 

#### Blinding of participants and personnel: All outcomes

- Prediction: Low risk
- Ground truth: Low risk
- Match: True
- Model rationale: A matched placebo and masked clinicians (with separated roles for evaluation and treatment) indicate effective blinding of participants and personnel; therefore, performance bias is unlikely to have materially influenced the outcomes.
- Model support: Quote: "Placebo matched for smell, taste, and viscosity was prepared at each site's pharmacy according to study specifications." Comment: Blinding of participants and personnel was implemented with a matched placebo and separate masked evaluating and treating clinicians, making it unlikely that knowledge of allocation materially influenced outcomes. Probably done.
- Model support context: [{"source": "methodology", "quote": "Placebo matched for smell, taste, and viscosity was prepared at each site's pharmacy according to study specifications.", "relevance": "Shows participants received a credible matched placebo, supporting participant blinding."}, {"source": "methodology", "quote": "Two masked clinicians met with participants during each scheduled evaluation. The evaluating clinician monitored efficacy and was blinded to adverse events. The treating clinician reviewed efficacy ratings, monitored and recorded adverse events, and subsequently adjusted the medication dosage as clinically indicated.", "relevance": "Indicates key study personnel were masked and roles separated to reduce risk of performance bias."}]
- GT support: Two masked clinicians met with participants during each scheduled evaluation
- Evidence row: {}
- Source context preview: 

#### Blinding of outcome assessment: All outcomes

- Prediction: Low risk
- Ground truth: Low risk
- Match: True
- Model rationale: Outcome assessment was performed by masked, trained clinicians, and the placebo was matched to medication, making it unlikely that assessors knew allocations or that lack of blinding biased outcome measurement; therefore risk of detection bias is low.
- Model support: Quote: "The evaluating clinician monitored efficacy and was blinded to adverse events. Evaluating clinicians from all sites were trained to reliability on the CYBOCS-PDD, CGI-I, and Clinical Global Impressions, Severity of Illness Scale at the beginning and midpoint of the trial." Comment: Blinded outcome assessment was implemented for efficacy measures by masked evaluating clinicians who were trained and thus unlikely to have their assessments influenced by knowledge of treatment allocation. Probably done.
- Model support context: [{"source": "methodology", "quote": "The evaluating clinician monitored efficacy and was blinded to adverse events. Evaluating clinicians from all sites were trained to reliability on the CYBOCS-PDD, CGI-I, and Clinical Global Impressions, Severity of Illness Scale at the beginning and midpoint of the trial.", "relevance": "Direct evidence that outcome assessors (evaluating clinicians) were blinded and trained on the outcome instruments—supports low detection bias for assessed outcomes."}, {"source": "methodology", "quote": "Placebo matched for smell, taste, and viscosity was prepared at each site's pharmacy according to study specifications.", "relevance": "Supports the integrity of participant blinding which reduces risk that assessors could infer allocation from participant behavior or reports."}]
- GT support: The evaluating clinician monitored efficacy and was blinded to AEs
- Evidence row: {}
- Source context preview: 

#### Incomplete outcome data: All outcomes

- Prediction: Low risk
- Ground truth: Unclear risk
- Match: False
- Model rationale: Overall attrition was modest (~17%) and similar in magnitude and reasons across arms; missing data were handled with LOCF and analyses used intent-to-treat. Given balanced missingness and no indication that reasons were related differentially to outcomes, risk of material bias from incomplete outcome data is low.
- Model support: Quote: "149 were randomized to receive citalopram (n=73) or placebo (n=76). Most participants (82.6%) completed the 12-week trial. In the citalopram-treated group, 12.3% stopped early due to adverse events and another 2.7% withdrew consent; in the placebo group, 9.2% left early owing to adverse events and another 6.6% withdrew consent. For subjects who failed to complete all postrandomization assessments, the last observation was carried forward." Comment: Attrition was moderate (≈17.4%) and similar in number and reasons across groups; investigators used ITT analyses and handled missing data with LOCF. The balance and similar reasons make bias unlikely (Probably done).
- Model support context: [{"source": "methodology", "quote": "149 were randomized to receive citalopram (n=73) or placebo (n=76). Most participants (82.6%) completed the 12-week trial. In the citalopram-treated group, 12.3% stopped early due to adverse events and another 2.7% withdrew consent; in the placebo group, 9.2% left early owing to adverse events and another 6.6% withdrew consent. For subjects who failed to complete all postrandomization assessments, the last observation was carried forward.", "relevance": "Provides numbers and reasons for attrition by group and the method used to handle missing data (LOCF) and states ITT principle was used."}]
- GT support: LTFU citalopram: 13 withdrew, 1 due to serious AE; 8 AEs; 2 protocol violations; 2 consent withdrawn LTFU placebo: 13 withdrawn, 7 AEs; 1 protocol violation; 5 consent withdrawn
- Evidence row: {}
- Source context preview: 


## 20579848 - Palacios 2009

- Mode: strict
- Review context: none (0 chars)
- Article chars: 25127
- Extraction context chars: 12003
- Total seconds: 95.67

### Methodology Extraction

- `randomization_method`: Not reported
- `allocation_concealment_method`: Not reported
- `blinding_participants`: The trial is described as "randomized, double-blind (single-blinded for the dairy group), placebo-controlled". Exact quote: "We conducted a single-center, randomized, double-blind (single-blinded for the dairy group), placebo-controlled trial for 21 wk to test the effects of calcium supplementation and dairy intake on body fat and serum lipids in obese Puerto Ricans."
- `blinding_personnel`: Not reported. The article does not specify who among study personnel (other than a general statement about blinding above) was blinded or how blinding of personnel was implemented.
- `blinding_outcome_assessors`: Partial information: "Measurements were taken ... by the CRC-trained personnel, who were blinded to the study treatments." Exact quote: "Measurements were taken while subjects wore light clothing, no shoes or accessories, by the CRC-trained personnel, who were blinded to the study treatments."
- `attrition_details`: Of the 46 subjects recruited, 10 did not qualify and 6 subjects retired before the initial visit. Therefore, 30 subjects were enrolled. "Five subjects dropped out from the study before the second visit; four females and one male. The reasons for not continuing in the study were as follows: one had medical reasons and four lost interest." Of the 25 subjects who completed the study, 20 were female and 5 were male. No further per-group attrition numbers, handling of missing data, or analyses...
- `study_design`: Single-center, randomized, placebo-controlled trial; described as "randomized, double-blind (single-blinded for the dairy group), placebo-controlled trial". Parallel group (three arms: high dairy, high elemental calcium, control) for 21 weeks.
- `additional_notes`: Interventions: subjects randomly assigned to three diets (high dairy, high elemental calcium [600 mg/d supplement], or control with placebo tablet). Dairy products were provided monthly and tailored to taste; supplements/placebo taken daily. Compliance monitored via calendar, food records, FFQ, and monthly 24-h recall. Subjects instructed to maintain usual physical activity and isocaloric intake. No details provided on the method of random sequence generation or on allocation concealment...

### Domain Judgements

| Domain | Pred | GT | Match | Error Type |
|---|---|---|---|---|
| Random sequence generation | Unclear risk | Low risk | no | under-called_due_to_missing_or_underused_evidence |
| Allocation concealment | Unclear risk | Low risk | no | under-called_due_to_missing_or_underused_evidence |
| Blinding of participants and personnel: All outcomes | High risk | Low risk / Not applicable | no | blinding_outcome_type_or_role_confusion |
| Blinding of outcome assessment: All outcomes | Low risk | Low risk / Not applicable | yes |  |
| Incomplete outcome data: All outcomes | Unclear risk | Not applicable / Unclear risk | yes |  |

### Audit Details

#### Random sequence generation

- Prediction: Unclear risk
- Ground truth: Low risk
- Match: False
- Model rationale: Because the paper only states that allocation was randomized without describing the random sequence generation method, there is insufficient information to judge whether a truly random process was used (Low risk) or a non-random rule was applied (High risk); therefore the risk is Unclear.
- Model support: Comment: The report states the trial was "randomized" but provides no description of the method used to generate the random allocation sequence. No random sequence generation procedure (e.g. computer generator, random number table) is reported, nor is any non-random method described.
- Model support context: [{"source": "methodology", "quote": "\"randomization_method\": \"Not reported\"", "relevance": "Direct statement that the method of random sequence generation was not reported."}, {"source": "methodology", "quote": "\"We conducted a single-center, randomized, double-blind (single-blinded for the dairy group), placebo-controlled trial for 21 wk to test the effects of calcium supplementation and dairy intake on body fat and serum lipids in obese Puerto Ricans.\"", "relevance": "Shows the trial is described as randomized, but does not give details on how the random sequence was generated."}]
- GT support: Comment: mail from Dr Palacios: "The random sequence was computer generated"
- Evidence row: {}
- Source context preview: 

#### Allocation concealment

- Prediction: Unclear risk
- Ground truth: Low risk
- Match: False
- Model rationale: Because the report gives no information on how allocations were concealed (e.g. central randomization, sealed envelopes) and randomization method is also not reported, there is insufficient detail to determine whether recruiters could have foreseen assignments; therefore risk of bias for allocation concealment is unclear.
- Model support: Comment: The article does not describe the method used to conceal allocation prior to assignment; allocation concealment not reported.
- Model support context: [{"source": "methodology", "quote": "allocation_concealment_method: \"Not reported\"", "relevance": "Direct statement that allocation concealment method is not described in the report."}, {"source": "methodology", "quote": "The trial is described as \"randomized, double-blind (single-blinded for the dairy group), placebo-controlled\".", "relevance": "Describes blinding generally but gives no details on how allocation was concealed from recruiters/enrollers, so cannot confirm concealment procedures."}, {"source": "methodology", "quote": "No details provided on the method of random sequence generation or on allocation concealment procedures.", "relevance": "Confirms absence of necessary information to judge whether assignment could be foreseen."}]
- GT support: Comment: mail from Dr Palacios: "The random sequence was computer generated and the allocation concealment was performed centrally"
- Evidence row: {}
- Source context preview: 

#### Blinding of participants and personnel: All outcomes

- Prediction: High risk
- Ground truth: Low risk / Not applicable
- Match: False
- Model rationale: Because the dairy arm was single-blinded and there is no information ensuring participants and key personnel were unaware of allocations (and outcomes like body fat and weight can be influenced by behaviour), lack of adequate blinding could have materially biased results, so risk of performance bias is high.
- Model support: Quote: "We conducted a single-center, randomized, double-blind (single-blinded for the dairy group), placebo-controlled trial for 21 wk to test the effects of calcium supplementation and dairy intake on body fat and serum lipids in obese Puerto Ricans." Comment: The report states blinding was double-blind but explicitly notes the dairy group was single-blinded, meaning participants/personnel could not be fully blinded to allocation for the dairy arm. Given primary outcomes (body fat, serum lipids, body weight) can be influenced by participant or personnel behaviours (dietary adherence, reporting, co-interventions) and the methods do not describe procedures to prevent unblinding of staff or participants in the dairy vs supplement/placebo comparisons, performance bias is likely. Outcome assessors for anthropometry were blinded, but that does not mitigate biased behaviours due to unblinded...
- Model support context: [{"source": "methodology", "quote": "\"randomized, double-blind (single-blinded for the dairy group), placebo-controlled trial\"", "relevance": "Direct statement of the blinding scheme indicating the dairy arm was only single-blinded."}, {"source": "methodology", "quote": "The article does not specify who among study personnel (other than a general statement about blinding above) was blinded or how blinding of personnel was implemented.", "relevance": "Lack of detail about personnel blinding increases concern that key staff or participants knew allocations, which could influence behaviours affecting outcomes."}, {"source": "methodology", "quote": "\"Measurements were taken ... by the CRC-trained personnel, who were blinded to the study treatments.\"", "relevance": "Outcome assessors for anthropometry were blinded, but this does not prevent performance bias from unblinded participants or...
- GT support: Quote from publication: "The design of the study, a randomized, double-blinded" Comment: mail from Dr Palacios: "All anthropometric measurements were done by the research staff of the Puerto Rico Clinical Research Center, who were blinded to the study" | Quote from publication: "The design of the study, a randomized, double-blinded" Comment: mail from Dr Palacios: "All anthropometric measurements were done by the research staff of the Puerto Rico Clinical Research Center, who were blinded to the study" | Quote from publication: "The design of the study, a randomized, double-blinded" Comment: mail from Dr Palacios: "All anthropometric measurements were done by the research staff of the Puerto Rico Clinical Research Center, who were blinded to the study" | Quote from publication: "The design of the study, a randomized, double-blinded" Comment: mail from Dr Palacios: "All anthropometric...
- Evidence row: {}
- Source context preview: 

#### Blinding of outcome assessment: All outcomes

- Prediction: Low risk
- Ground truth: Low risk / Not applicable
- Match: True
- Model rationale: The study explicitly states that CRC-trained personnel who took measurements were blinded to treatment, meaning outcome assessment was performed without knowledge of allocation, which makes it unlikely that detection bias affected the measured outcomes.
- Model support: Quote: "Measurements were taken ... by the CRC-trained personnel, who were blinded to the study treatments." Comment: Outcome assessment for body measurements was performed by assessors who were explicitly stated to be blinded to treatment, so detection bias for these objective outcomes is unlikely. Although blinding was qualified (double-blind except single-blinded for the dairy group), the key outcome assessments were done by blinded CRC-trained personnel. Probably done.
- Model support context: [{"source": "methodology", "quote": "\"Measurements were taken ... by the CRC-trained personnel, who were blinded to the study treatments.\"", "relevance": "Direct statement that outcome assessors (for measurements) were blinded supports low risk of detection bias for those outcomes."}, {"source": "methodology", "quote": "\"randomized, double-blind (single-blinded for the dairy group), placebo-controlled trial\"", "relevance": "Overall blinding scheme indicates attempts at blinding; potential unblinding in dairy arm noted but does not negate that assessors were blinded."}]
- GT support: Blind outcome assessors | Blind outcome assessors | Quote from publication: "The design of the study, a randomized, double-blinded" Comment: mail from Dr Palacios: "All anthropometric measurements were done by the research staff of the Puerto Rico Clinical Research Center, who were blinded to the study." | Blind outcome assessors | Blind outcome assessors | Quote from publication: "The design of the study, a randomized, double-blinded" Comment: mail from Dr. Palacios: "All anthropometric measurements were done by the research staff of the Puerto Rico Clinical Research Center, who were blinded to the study."
- Evidence row: {}
- Source context preview: 

#### Incomplete outcome data: All outcomes

- Prediction: Unclear risk
- Ground truth: Not applicable / Unclear risk
- Match: True
- Model rationale: Although overall attrition (5/30, ~17%) and reasons are reported, the absence of per-group dropout numbers and no description of how missing outcome data were handled means we cannot determine whether missingness is likely related to outcomes or imbalanced across groups; thus risk of bias is unclear.
- Model support: Quote: "Five subjects dropped out from the study before the second visit; four females and one male. The reasons for not continuing in the study were as follows: one had medical reasons and four lost interest." Comment: Attrition is reported (5/30 = 16.7% overall) with reasons given, but no per-group dropout numbers, no information on whether missing data were balanced across arms, and no description of how missing outcome data were handled or imputed. Therefore there is insufficient information to judge the likely impact of missing data on outcomes.
- Model support context: [{"source": "methodology", "quote": "Of the 46 subjects recruited, 10 did not qualify and 6 subjects retired before the initial visit. Therefore, 30 subjects were enrolled. \"Five subjects dropped out from the study before the second visit; four females and one male. The reasons for not continuing in the study were as follows: one had medical reasons and four lost interest.\" Of the 25 subjects who completed the study, 20 were female and 5 were male. No further per-group attrition numbers, handling of missing data, or analyses methods for missing data are reported.", "relevance": "Provides the only attrition information; shows overall amount and reasons but lacks per-arm breakdown and handling methods needed to assess bias."}, {"source": "methodology", "quote": "Parallel group (three arms: high dairy, high elemental calcium, control) for 21 weeks.", "relevance": "With three arms,...
- GT support: 20 participants randomised and 17 assessed | 20 participants randomised and 17 assessed | Quote from publication: "There were no significant differences in the subject characteristics between those who completed and those who did not complete the study (data not shown). Of the 25 subjects who completed the study, 20 were female and 5 were male. Within the ﬁve males, one was allocated to the high dairy group, two to the high calcium group, and two to the control group." Comment: attrition rates were 10% and 20% but relating to a small number of randomised participants (N = 10) in both groups | 20 participants randomised and 17 assessed | 20 participants randomised and 17 assessed | Quote from publication: "There were no significant differences in the subject characteristics between those who completed and those who did not complete the study (data not shown). Of the 25 subjects who...
- Evidence row: {}
- Source context preview: 


## 21775755 - Ziegler 2011

- Mode: strict
- Review context: none (0 chars)
- Article chars: 24371
- Extraction context chars: 12003
- Total seconds: 89.05

### Methodology Extraction

- `randomization_method`: Patients were assigned to the two treatment groups according to a randomization list generated by the Biostatistics Department of MEDA Pharma. The random allocation was balanced using an undisclosed block size of six.
- `allocation_concealment_method`: The investigators and the monitor received sealed envelopes to enable decoding the individual blinded treatment in case of emergency.
- `blinding_participants`: randomized, double-blind, placebo-controlled ... film-coated tablets containing 600 mg ALA ... or matching placebo tablets with increased amounts of cellulose and lactose that were identical in appearance
- `blinding_personnel`: The trial was ... double-blind ... The investigators and the monitor received sealed envelopes to enable decoding the individual blinded treatment in case of emergency.
- `blinding_outcome_assessors`: Experienced, trained, and certified (by P.J.D. and colleagues) physicians evaluated the NIS and NSC. The nerve conduction, quantitative sensory tests (QSTs), and autonomic tests were performed by trained and certified personnel (by P.A.L., W.J.L., P.J.D., and colleagues). All results were interactively evaluated by the Reading and Quality Assurance Centers (at Mayo Clinic and Health Partners). Eligibility, baseline conditions, wave forms, stimulus response patterns, and test values were also...
- `attrition_details`: Not reported
- `study_design`: multicenter, randomized, double-blind, placebo-controlled, two-arm, 1:1 allocation ratio, parallel-group clinical trial
- `additional_notes`: Randomized patients were additionally assigned a four-digit randomization number at baseline. The trial consisted of a 2-week screening phase, 6-week placebo run-in phase, 4-year double-blind phase, and 4-week washout phase. An interim analysis was performed as soon as the 2-year data of most subjects were available; investigators/monitor had sealed envelopes for emergency decoding.

### Domain Judgements

| Domain | Pred | GT | Match | Error Type |
|---|---|---|---|---|
| Random sequence generation | Low risk | Low risk | yes |  |
| Allocation concealment | Unclear risk | Low risk | no | under-called_due_to_missing_or_underused_evidence |
| Blinding of participants and personnel: All outcomes | Low risk | Low risk | yes |  |
| Blinding of outcome assessment: All outcomes | Low risk | Low risk | yes |  |
| Incomplete outcome data: All outcomes | Unclear risk | High risk | no | under-called_due_to_missing_or_underused_evidence |

### Audit Details

#### Random sequence generation

- Prediction: Low risk
- Ground truth: Low risk
- Match: True
- Model rationale: The allocation sequence was generated centrally by the Biostatistics Department (a randomization list) with blocked randomization, which is an acceptable random method per Cochrane criteria, so risk of bias from inadequate random sequence generation is low.
- Model support: Quote: "Patients were assigned to the two treatment groups according to a randomization list generated by the Biostatistics Department of MEDA Pharma. The random allocation was balanced using an undisclosed block size of six." Comment: Probably done — a centrally generated randomization list using a biostatistics department and use of blocked randomization indicates a random component in sequence generation and supports low risk.
- Model support context: [{"source": "methodology", "quote": "Patients were assigned to the two treatment groups according to a randomization list generated by the Biostatistics Department of MEDA Pharma. The random allocation was balanced using an undisclosed block size of six.", "relevance": "Describes a random component (central biostatistics-generated list and blocked randomization) directly relevant to the sequence generation domain."}, {"source": "methodology", "quote": "Randomized patients were additionally assigned a four-digit randomization number at baseline.", "relevance": "Supports that a formal randomization system was used for allocation identifiers, consistent with proper sequence generation."}]
- GT support: Quote: "a randomization list was generated by the biostatistics department of the manufacturer of the study drug ..."
- Evidence row: {}
- Source context preview: 

#### Allocation concealment

- Prediction: Unclear risk
- Ground truth: Low risk
- Match: False
- Model rationale: While sequence generation appears independent, the report lacks sufficient detail on how assignments were concealed from those enrolling participants (no description of central allocation or adequately described sealed-envelope procedures). Therefore allocation concealment cannot be judged and is rated Unclear risk.
- Model support: Comment: Randomization list was generated centrally by the Biostatistics Department and investigators/monitor held sealed envelopes for emergency decoding, but there is no clear description that allocation was concealed from those enrolling participants (e.g. central allocation procedure, or that envelopes were sequentially numbered, opaque and sealed for routine concealment). Probably done but insufficient detail to be sure.
- Model support context: [{"source": "methodology", "quote": "Patients were assigned to the two treatment groups according to a randomization list generated by the Biostatistics Department of MEDA Pharma. The random allocation was balanced using an undisclosed block size of six.", "relevance": "Shows random sequence was generated by an independent biostatistics department (sequence generation), but does not by itself prove allocation concealment."}, {"source": "methodology", "quote": "The investigators and the monitor received sealed envelopes to enable decoding the individual blinded treatment in case of emergency.", "relevance": "Indicates envelopes existed for emergency unblinding, but does not state these were the method used to conceal allocation at enrolment nor that they were sequentially numbered, opaque and sealed as required to judge concealment as adequate."}]
- GT support: Quote: "a randomization list was generated by the biostatistics department of the manufacturer of the study drug, at distance of the centers the study took place"; "the random allocation was balanced using an undisclosed block size of six."
- Evidence row: {}
- Source context preview: 

#### Blinding of participants and personnel: All outcomes

- Prediction: Low risk
- Ground truth: Low risk
- Match: True
- Model rationale: The trial is explicitly described as double-blind with matching placebo tablets and emergency sealed envelopes for decoding, and outcomes were assessed by trained personnel and centralized centers; therefore it is unlikely that knowledge of allocation influenced performance or outcome assessment.
- Model support: Quote: "randomized, double-blind, placebo-controlled ... film-coated tablets containing 600 mg ALA ... or matching placebo tablets with increased amounts of cellulose and lactose that were identical in appearance" Comment: Blinding of participants and study personnel was implemented with matching placebo tablets and the trial is described as double-blind; emergency sealed decoding envelopes were available but would not routinely unblind. Probably done.
- Model support context: [{"source": "methodology", "quote": "randomized, double-blind, placebo-controlled ... film-coated tablets containing 600 mg ALA ... or matching placebo tablets with increased amounts of cellulose and lactose that were identical in appearance", "relevance": "Shows participants received identical-appearing active and placebo tablets, supporting successful participant blinding."}, {"source": "methodology", "quote": "The trial was ... double-blind ... The investigators and the monitor received sealed envelopes to enable decoding the individual blinded treatment in case of emergency.", "relevance": "Indicates investigators and personnel were blinded, with emergency decoding only available if needed, supporting maintained blinding of personnel."}, {"source": "methodology", "quote": "Experienced, trained, and certified (by P.J.D. and colleagues) physicians evaluated the NIS and NSC. The nerve...
- GT support: Quote: "... matching placebo tablets with increased amounts of cellulose and lactose that were identical in appearance." Comment: trial described as double-blind.
- Evidence row: {}
- Source context preview: 

#### Blinding of outcome assessment: All outcomes

- Prediction: Low risk
- Ground truth: Low risk
- Match: True
- Model rationale: The study implemented double-blinding with matching placebo and used trained, certified assessors plus centralized reading, making it unlikely that outcome assessment was influenced by knowledge of allocation, satisfying Low risk criteria.
- Model support: Comment: The trial is described as randomized, double-blind, placebo-controlled with matching placebo tablets identical in appearance; outcome measurements (NIS, NSC, nerve conduction, QSTs, autonomic tests) were performed by trained and certified personnel and centrally evaluated by Reading and Quality Assurance Centers, making it unlikely that outcome assessment was influenced by knowledge of allocation. Probably done.
- Model support context: [{"source": "methodology", "quote": "randomized, double-blind, placebo-controlled ... film-coated tablets containing 600 mg ALA ... or matching placebo tablets with increased amounts of cellulose and lactose that were identical in appearance", "relevance": "Shows participant and personnel blinding with indistinguishable placebo, which reduces chance assessors learned allocation from treatment appearance or procedures."}, {"source": "methodology", "quote": "Experienced, trained, and certified (by P.J.D. and colleagues) physicians evaluated the NIS and NSC. The nerve conduction, quantitative sensory tests (QSTs), and autonomic tests were performed by trained and certified personnel (by P.A.L., W.J.L., P.J.D., and colleagues). All results were interactively evaluated by the Reading and Quality Assurance Centers (at Mayo Clinic and Health Partners).", "relevance": "Indicates outcome...
- GT support: Quote: "The investigators and the monitor received sealed envelopes to enable decoding the individual blinded treatment in case of emergency."
- Evidence row: {}
- Source context preview: 

#### Incomplete outcome data: All outcomes

- Prediction: Unclear risk
- Ground truth: High risk
- Match: False
- Model rationale: There is no reported information on the amount, reasons, balance between groups, or handling/imputation of missing outcome data; per Cochrane criteria this lack of reporting leads to an Unclear risk judgment.
- Model support: Comment: No information about numbers or reasons for missing outcome data was reported, so it is not possible to assess whether attrition could bias the results.
- Model support context: [{"source": "methodology", "quote": "attrition_details: \"Not reported\"", "relevance": "Direct statement that attrition/outcome missing-data details were not reported; prevents assessment of amount, reasons, balance, or handling of missing data."}, {"source": "methodology", "quote": "The trial consisted of a 2-week screening phase, 6-week placebo run-in phase, 4-year double-blind phase, and 4-week washout phase.", "relevance": "Long follow-up (4 years) increases risk that attrition could be substantial and materially affect outcomes, making missing-data reporting important."}]
- GT support: More than 40% of participants discontinued intervention in both groups during the 4-year study. We do not know how many participants were lost before the outcomes at 2 years (our outcome of interest), and how many after the first 2 years. Most participants (454/460) were included in the ITT analysis, but the study authors did not report for how many they managed to measure the outcome, and for how many they used the last observation carried forward ("mean of weeks 191 and 192 or last available value after randomization"). Apparently, the proportion of dropouts and the causes of dropout were equally distributed among the 2 groups.
- Evidence row: {}
- Source context preview: 


## 23148458 - Sheridan 2012

- Mode: strict
- Review context: none (0 chars)
- Article chars: 34179
- Extraction context chars: 12003
- Total seconds: 92.43

### Methodology Extraction

- `randomization_method`: Randomization used computer-generated random numbers that were sealed in opaque envelopes.
- `allocation_concealment_method`: Randomization used computer-generated random numbers that were sealed in opaque envelopes.
- `blinding_participants`: Not reported
- `blinding_personnel`: Not reported
- `blinding_outcome_assessors`: Physicians... were notified only about patients’ participation, but not group assignment
- `attrition_details`: Not reported
- `study_design`: Randomized controlled trial (two randomized controlled trials combined; convenience sample within practices, participants randomized within practices)
- `additional_notes`: Participants were randomized within practices. Interventions were delivered prior to regularly scheduled medical appointments in a private room. Men in intervention groups received a video and a coaching session guided by a trained research assistant; control viewed an unrelated highway safety video without coaching. Data combined from two trials conducted in different cities with identical implementation and measurement strategies.

### Domain Judgements

| Domain | Pred | GT | Match | Error Type |
|---|---|---|---|---|
| Random sequence generation | Low risk | Low risk | yes |  |
| Allocation concealment | Low risk | Low risk | yes |  |
| Blinding of participants and personnel: All outcomes | High risk | Low risk | no | blinding_outcome_type_or_role_confusion |
| Blinding of outcome assessment: All outcomes | Low risk | Low risk | yes |  |
| Incomplete outcome data: All outcomes | Unclear risk | Low risk | no | under-called_due_to_missing_or_underused_evidence |

### Audit Details

#### Random sequence generation

- Prediction: Low risk
- Ground truth: Low risk
- Match: True
- Model rationale: The report explicitly states that allocation used computer-generated random numbers, which is an appropriate random method per Cochrane criteria, indicating a low risk of bias from sequence generation.
- Model support: Quote: "Randomization used computer-generated random numbers that were sealed in opaque envelopes." Comment: Probably done — the investigators report a random component (computer-generated random numbers), which meets the criteria for adequate sequence generation.
- Model support context: [{"source": "methodology", "quote": "Randomization used computer-generated random numbers that were sealed in opaque envelopes.", "relevance": "Describes the random component of sequence generation (computer-generated random numbers), directly addressing the random sequence generation domain."}]
- GT support: Randomisation used computer‐generated random numbers that were sealed in opaque envelopes.
- Evidence row: {}
- Source context preview: 

#### Allocation concealment

- Prediction: Low risk
- Ground truth: Low risk
- Match: True
- Model rationale: The study reports that computer-generated random numbers were sealed in opaque envelopes, an appropriate allocation concealment method that makes it unlikely that those enrolling participants could foresee assignments, meeting criteria for low risk of selection bias.
- Model support: Quote: "Randomization used computer-generated random numbers that were sealed in opaque envelopes." Comment: Probably done — allocation was concealed using sealed opaque envelopes, which prevents recruiters/enrollers from foreseeing assignments.
- Model support context: [{"source": "methodology", "quote": "Randomization used computer-generated random numbers that were sealed in opaque envelopes.", "relevance": "Describes the method used to conceal allocation; sealed opaque envelopes are an accepted method for preventing foreknowledge of upcoming assignments."}, {"source": "methodology", "quote": "Participants were randomized within practices. Interventions were delivered prior to regularly scheduled medical appointments in a private room.", "relevance": "Provides context on who enrolled participants and when allocation needed to be concealed, supporting the importance of the envelope method in this setting."}]
- GT support: Randomisation used computer‐generated random numbers that were sealed in opaque envelopes.
- Evidence row: {}
- Source context preview: 

#### Blinding of participants and personnel: All outcomes

- Prediction: High risk
- Ground truth: Low risk
- Match: False
- Model rationale: Because blinding of participants and personnel was not reported and the interventions were quite different (coaching vs no coaching), participants and staff almost certainly knew allocation; this knowledge could materially influence patient-reported decision-making outcomes, so risk of performance bias is high.
- Model support: Comment: Blinding of participants and personnel not reported; interventions clearly differed (intervention: video + coaching session by research assistant in private room; control: unrelated highway safety video without coaching), so participants and personnel were likely aware of allocation and outcomes (patient-reported decision-making) could have been influenced.
- Model support context: [{"source": "methodology", "quote": "Men in intervention groups received a video and a coaching session guided by a trained research assistant; control viewed an unrelated highway safety video without coaching.", "relevance": "Shows interventions were dissimilar and delivery involved research staff, making blinding of participants and personnel unlikely."}, {"source": "methodology", "quote": "blinding_participants: Not reported; blinding_personnel: Not reported", "relevance": "No information that participants or personnel were blinded."}, {"source": "methodology", "quote": "Physicians... were notified only about patients’ participation, but not group assignment", "relevance": "Even if physicians were masked to assignment, participants and the research assistants delivering coaching likely were not, which is important because outcomes include patient-reported decision-making."}]
- GT support: "Men then proceeded to their visit with their physician (who was notified only about patients’ participation, but not group assignment)." Although described as single‐masked in the study registration, due to the attention control intervention in the control groups, both participants and staff could be considered blinded.
- Evidence row: {}
- Source context preview: 

#### Blinding of outcome assessment: All outcomes

- Prediction: Low risk
- Ground truth: Low risk
- Match: True
- Model rationale: The report explicitly states physicians assessing outcomes were not informed of group assignments and interventions were delivered privately before routine appointments, making it unlikely that assessors knew allocation; therefore detection bias is likely low.
- Model support: Quote: "Physicians... were notified only about patients’ participation, but not group assignment" Comment: The study reports that physicians (outcome assessors) were not informed of group assignment, indicating blinding of outcome assessment; outcomes include patient-reported decision-making but assessor blinding reduces detection bias. Probably done.
- Model support context: [{"source": "methodology", "quote": "blinding_outcome_assessors: Physicians... were notified only about patients’ participation, but not group assignment", "relevance": "States that outcome assessors (physicians) were not informed of treatment allocation, which supports blinding of outcome assessment and lowers detection bias risk."}, {"source": "methodology", "quote": "Participants were randomized within practices. Interventions were delivered prior to regularly scheduled medical appointments in a private room. Men in intervention groups received a video and a coaching session guided by a trained research assistant; control viewed an unrelated highway safety video without coaching.", "relevance": "Describes intervention delivery and that assessors (physicians) encountered patients at appointments without knowledge of assignment, making it unlikely they could deduce allocation and...
- GT support: Self‐reported outcome measures, therefore, low risk considering masking of participants.
- Evidence row: {}
- Source context preview: 

#### Incomplete outcome data: All outcomes

- Prediction: Unclear risk
- Ground truth: Low risk
- Match: False
- Model rationale: Because the report provides no information on the amount, reasons or handling of missing outcome data, we cannot determine whether missingness is balanced or related to outcomes, nor whether appropriate imputation was used; therefore the risk of bias due to incomplete outcome data is unclear.
- Model support: Comment: Attrition details and handling of missing outcome data are not reported in the available methodological information, so it is not possible to judge whether missing data could bias the results.
- Model support context: [{"source": "methodology", "quote": "attrition_details: \"Not reported\"", "relevance": "Direct indication that the study report did not provide information on numbers lost to follow-up or reasons for missing outcome data, which is essential to assess attrition bias."}, {"source": "methodology", "quote": "Participants were randomized within practices. Interventions were delivered prior to regularly scheduled medical appointments in a private room. Men in intervention groups received a video and a coaching session guided by a trained research assistant; control viewed an unrelated highway safety video without coaching.", "relevance": "Gives context about study procedures but does not provide any information about completeness of outcome data or how missing data were handled."}]
- GT support: SeeFigure 1for reporting on missing data (only 2 participants in intervention group due to false inclusion)
- Evidence row: {}
- Source context preview: 

## Workflow Evolution Notes

- Inspect mismatches where prediction is `Unclear risk` but GT is `Low risk`: these usually mean retrieval or Stage 1 extraction missed a concrete methodological phrase.
- Inspect mismatches where prediction is `Low risk` or `High risk` but GT is `Unclear risk`: these usually mean the prompt is allowing too much inference from generic trial language.
- For blinding mismatches, add outcome-type cues to the prompt: self-report outcomes, objective outcomes, assessor-administered outcomes, and whether lack of blinding can materially affect the outcome.
- For allocation concealment mismatches, require the model to distinguish sequence generation from concealment before assignment.